A trader works on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., March 5, 2020.
Andrew Kelly/Reuters
Moderna and BioNTech both fell more than 15% on Friday after Merck announced positive results for its antiviral COVID-19 pill.Merck’s antiviral cut hospitalizations and deaths in half for those infected with COVID-19.The drug is another option to help curtail the pandemic as countries struggle to reach herd immunity via vaccinations.Sign up here for our daily newsletter,
https://markets.businessinsider.com/news/stocks/moderna-biontech-stock-price-covid-merck-antiviral-drug-pill-novavax-2021-10
